3月9日 - ** 药物开发商Rapport Therapeutics RAPP.O股价盘前上涨6.45%至32.19美元
** 公司称已授予Tenacia其实验性癫痫药物RAP-219的大中华区独家代理权
** 该公司称，RAPP的RAP-219旨在治疗局灶性癫痫发作（一种癫痫发作始于大脑的一个区域）和双相躁狂症。
** 该公司称，Tenacia公司将在中国进行试验并将该药物商业化；Rapport公司将获得2,000万美元的预付款，以及高达3.08亿美元的里程碑和特许权使用费。
** 公司表示，RAP-219在一项早期研究中显示癫痫发作减少且耐受性良好
** 两家公司计划今年晚些时候开始全球后期试验 - RAPP
** 2025 年股价上涨约 71%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.